Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,929 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dose level 4 Clear all
Recruiting Phase 1 Interventional

A Study of MGC028 in Participants With Advanced Solid Tumors

NCT06723236
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Interventions
MGC028
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400
View directory record Official record
Conditions
Breast Cancer, Solid Tumors
Interventions
PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

NCT00024167
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
40
States / cities
Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Early Phase 1 Interventional

Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

NCT03125811
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Inhaled Isopropyl Alcohol (IPA), Oral Dissolvable Tablet Zofran (ondansetron)
Other · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 4 Interventional

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

NCT00418600
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

NCT01058707
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MLN0128
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

NCT01982292
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
RLX030 (serelaxin), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Anaheim, California • Colorado Springs, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

NCT01987492
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Early Phase 1 Interventional Results available

Low Dose Vasopressin in Traumatic Shock

NCT00420407
View directory record Official record
Conditions
Injuries, Shock, Traumatic
Interventions
normal saline control, vasopressin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

NCT03861871
View directory record Official record
Conditions
CDD
Interventions
Fenfluramine Hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

A Study of AG-80308 in Dry Eye Patients

NCT05372107
View directory record Official record
Conditions
Dry Eye Disease
Interventions
AG-80308
Drug
Lead sponsor
Allgenesis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Newport Beach, California • Raynham, Massachusetts • Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

NCT00136292
View directory record Official record
Conditions
Gram-positive Bacterial Infections
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Kansas City, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 23, 2026, 8:17 AM EDT
Recruiting Phase 1 Interventional

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

NCT06816992
View directory record Official record
Conditions
Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
Interventions
ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New York, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

NCT03566511
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

NCT03710707
View directory record Official record
Conditions
Parkinson Disease
Interventions
DNL201, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy

NCT00535392
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
La Jolla, California • Boston, Massachusetts • Chesterfield, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional

DUR-928 in Patients With Alcoholic Hepatitis

NCT03917407
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 (Moderate AH), DUR-928 (Severe AH)
Drug
Lead sponsor
Craig James McClain
Other
Eligibility
21 Years to 67 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 23, 2026, 8:17 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00996892
View directory record Official record
Conditions
Solid Tumors
Interventions
Cobimetinib, Pictilisib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06124807
View directory record Official record
Conditions
Obesity, Overweight and Obesity
Interventions
Mazdutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 8:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Remifentanil in Adults With OSA

NCT02898792
View directory record Official record
Conditions
Apnea, Sleep
Interventions
Targeted infusion of remifentanil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 23, 2026, 8:17 AM EDT